- Molecular NameRivastigmine
- SynonymEna 713 Free Base; rivastigmine; Rivastigmine Hydrogen Tartrate
- Weight250.342
- Drugbank_IDDB00989
- ACS_NO123441-03-2
- Show 3D model
- LogP (experiment)2.611
- LogP (predicted, AB/LogP v2.0)2.27
- pka8.99
- LogD (pH=7, predicted)0.79
- Solubility (experiment)Highly soluble
- LogS (predicted, ACD/Labs)(ph=7)0.6
- LogSw (predicted, AB/LogsW2.0)16.45
- Sw (mg/ml) (predicted, ACD/Labs)26.85
- No.of HBond Donors0
- No.of HBond Acceptors4
- No.of Rotatable Bonds5
- TPSA32.78
- StatusFDA approved
- AdministrationOral, Transdermal
- PharmacologyA parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer’s type and dementia due to Parkinson's disease.
- Absorption_value98.0
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability72.0
- Protein binding40.0
- Volume of distribution (VD)2.3 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmRivastigmine is metabolized by cholinesterase. No apparent gender differences.
- Half life1.4 h
- ExcretionRenal, 97%
- Urinary ExcretionNegligible
- Clerance13 ml/min/kg
- ToxicityThe most common adverse events leading to discontinuation, defined as those occurring in at least 2% of patients and at twice the incidence seen in placebo patients include nausea, vomiting, anorexia, dizziness.
- LD50 (rat)N/A
- LD50 (mouse)LD50>6